Preventing infections in blood cancer patients with low white cells
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests whether taking Xerava (an antibiotic) can prevent serious infections in people who have prolonged low neutrophils after chemotherapy or transplant preparation. If it works, it may lower the risk of infections during the highest-risk period after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting treatment for acute leukemia, or getting ready for a stem cell transplant (HSCT)
- You can give informed consent (or your legal guardian can)
- Your liver blood tests are not too high: bilirubin is within 3 times normal, and AST/ALT are within 5 times normal
- You do not have an uncontrolled ongoing infection (bacterial, viral, or fungal) when you start
- You are not being actively treated for a current urine infection (UTI)
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if mavorixafor can help people with certain types of long-term low neutrophil counts (chronic neutropenia) who still get frequent or serious infections. It aims to reduce infection risk by boosting your body's infection-fighting cells.
This study looks at when to start antibiotics early for blood cancer patients who may be carrying resistant bacteria (that are hard to treat). It aims to find the best time to treat these infections to improve outcomes.
This study looks at patients with blood cancers who may carry bacteria that are resistant to many antibiotics. It aims to find which patients are more likely to get sick from these bacteria, so doctors can better protect them.
This study looks at how well the antibiotic eravacycline works in seriously ill patients who have not improved with other antibiotics. It aims to understand how the drug behaves in the body to help guide dosing and improve treatment.
This trial tests whether giving a preventive antibiotic during chemotherapy can lower the risk of infections in people with certain blood cancers. It may help reduce hospital stays and improve treatment outcomes.
This study tests a combination treatment using eravacycline, an antibiotic, for pneumonia caused by bacteria that are resistant to many other antibiotics. It aims to see if this treatment can help patients who have not responded to standard care.
Hear when a new Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.